English   español  
Please use this identifier to cite or link to this item: http://hdl.handle.net/10261/180482
logo share SHARE logo core CORE   Add this article to your Mendeley library MendeleyBASE

Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL
Exportar a otros formatos:

PDGF restores the defective phenotype of adipose-derived mesenchymal stromal cells from diabetic patients

AuthorsCapilla-González, Vivian; López-Beas, Javier; Escacena, Natalia ; Aguilera, Yolanda ; Cuesta, Antonio de la; Ruiz-Salmerón, Rafael; Martín, Franz ; Hmadcha, Abdelkrim ; Soria Escoms, Bernat
KeywordsAdipose-derived mesenchymal stromal cells
Thrombotic state
Critical limb ischemia
Issue Date7-Nov-2018
CitationMolecular Therapy 26(11): 2696-2709 (2018)
AbstractDiabetes is a chronic metabolic disorder that affects 415 million people worldwide. This pathology is often associated with long-term complications, such as critical limb ischemia (CLI), which increases the risk of limb loss and mortality. Mesenchymal stromal cells (MSCs) represent a promising option for the treatment of diabetes complications. Although MSCs are widely used in autologous cell-based therapy, their effects may be influenced by the constant crosstalk between the graft and the host, which could affect the MSC fate potential. In this context, we previously reported that MSCs derived from diabetic patients with CLI have a defective phenotype that manifests as reduced fibrinolytic activity, thereby enhancing the thrombotic risk and compromising patient safety. Here, we found that MSCs derived from diabetic patients with CLI not only exhibit a prothrombotic profile but also have altered multi-differentiation potential, reduced proliferation, and inhibited migration and homing to sites of inflammation. We further demonstrated that this aberrant cell phenotype is reversed by the platelet-derived growth factor (PDGF) BB, indicating that PDGF signaling is a key regulator of MSC functionality. These findings provide an attractive approach to improve the therapeutic efficacy of MSCs in autologous therapy for diabetic patients.
Publisher version (URL)https://doi.org/10.1016/j.ymthe.2018.08.011
Appears in Collections:(CABIMER) Artículos
Files in This Item:
File Description SizeFormat 
accesoRestringido.pdf15,38 kBAdobe PDFThumbnail
Show full item record
Review this work

Related articles:

WARNING: Items in Digital.CSIC are protected by copyright, with all rights reserved, unless otherwise indicated.